When using CpG-siRNA conjugates that specifically silence STAT3 in TLR9-positive myeloid cells in mouse prostate cancer cells, the downstream STAT3 pathway activation blockage decreased the expression and activity of Arg-1, thus weakening the immunosuppression ability of MDSCs (141). Here, STAT3 is linked to prostate carcinoma.